Sarepta Therapeutics, Inc. (SRPT)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
21.55 USD
+0.38
(1.795%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 21.53 -0.02 (-0.020%) ⇩ (April 17, 2026, 7:51 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:01 p.m. EDT
SRPT is experiencing a volatile price movement with recent swings and mixed analyst sentiment. The fundamental data shows a high level of risk and negative profitability, which is concerning for long-term investors. The lack of dividends and the forecasting model's negative direction suggest that short-term traders should be cautious. While there are signs of potential momentum, the overall picture is bearish, and the stock appears to be overvalued relative to its fundamentals. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.148533 |
| MSTL | 0.155694 |
| AutoETS | 0.156825 |
| AutoARIMA | 0.157043 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.102 |
| Excess Kurtosis | -1.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 91.139 |
| Revenue per Share | 21.956 |
| Market Cap | 2,262,529,536 |
| Forward P/E | 7.17 |
| Beta | 0.28 |
| Profit Margins | -32.45% |
| Website | https://www.sarepta.com |
As of April 11, 2026, 3:01 p.m. EDT: Options activity indicates mixed sentiment. There are notable IV spikes and OI walls at various strike prices, suggesting uncertainty or potential for significant price movements. The ATM IV has been fluctuating, with some expirations showing higher volatility. The presence of major OI walls at certain strikes suggests that speculators are positioning for potential price changes, but the overall trend is unclear. The recent price swings and the forecasting model's negative prediction indicate caution for short-term traders.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.61669385 |
| Address1 | 215 First Street |
| Address2 | Suite 415 |
| All Time High | 181.83 |
| All Time Low | 2.7 |
| Ask | 21.9 |
| Ask Size | 22 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.8 - Hold |
| Average Daily Volume10 Day | 2,281,940 |
| Average Daily Volume3 Month | 2,852,973 |
| Average Volume | 2,852,973 |
| Average Volume10Days | 2,281,940 |
| Beta | 0.283 |
| Bid | 21.15 |
| Bid Size | 22 |
| Board Risk | 3 |
| Book Value | 10.867 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.55 |
| Current Ratio | 2.317 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 21.7481 |
| Day Low | 21.02 |
| Debt To Equity | 91.139 |
| Display Name | Sarepta Therapeutics |
| Earnings Call Timestamp End | 1,772,055,000 |
| Earnings Call Timestamp Start | 1,772,055,000 |
| Earnings Timestamp | 1,772,053,200 |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | -613,251,008 |
| Ebitda Margins | -0.27897 |
| Enterprise To Ebitda | -3.852 |
| Enterprise To Revenue | 1.075 |
| Enterprise Value | 2,362,427,648 |
| Eps Current Year | 3.99378 |
| Eps Forward | 3.00516 |
| Eps Trailing Twelve Months | -7.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.9366 |
| Fifty Day Average Change | 2.6133995 |
| Fifty Day Average Change Percent | 0.13800785 |
| Fifty Two Week Change Percent | -61.669384 |
| Fifty Two Week High | 64.8 |
| Fifty Two Week High Change | -43.250004 |
| Fifty Two Week High Change Percent | -0.6674383 |
| Fifty Two Week Low | 10.42 |
| Fifty Two Week Low Change | 11.129999 |
| Fifty Two Week Low Change Percent | 1.0681381 |
| Fifty Two Week Range | 10.42 - 64.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 865,431,000,000 |
| Float Shares | 91,782,059 |
| Forward Eps | 3.00516 |
| Forward P E | 7.1709986 |
| Free Cashflow | 95,917,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 835 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | -0.07435 |
| Gross Profits | -163,434,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05152 |
| Held Percent Institutions | 0.90242 |
| Implied Shares Outstanding | 104,989,772 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,342,051,200 |
| Last Split Factor | 1:6 |
| Long Business Summary | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Sarepta Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,262,529,536 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_362584 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -713,409,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,221,058,626 |
| Number Of Analyst Opinions | 23 |
| Open | 21.23 |
| Operating Cashflow | -205,479,008 |
| Operating Margins | -0.92584 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | -0.09 |
| Phone | 617 274 4000 |
| Post Market Change | -0.01999855 |
| Post Market Change Percent | -0.0928007 |
| Post Market Price | 21.53 |
| Post Market Time | 1,776,469,886 |
| Previous Close | 21.17 |
| Price Eps Current Year | 5.3958907 |
| Price Hint | 2 |
| Price To Book | 1.983068 |
| Price To Sales Trailing12 Months | 1.0292474 |
| Profit Margins | -0.32454 |
| Quick Ratio | 1.332 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.76 |
| Region | US |
| Regular Market Change | 0.379999 |
| Regular Market Change Percent | 1.79499 |
| Regular Market Day High | 21.7481 |
| Regular Market Day Low | 21.02 |
| Regular Market Day Range | 21.02 - 21.7481 |
| Regular Market Open | 21.23 |
| Regular Market Previous Close | 21.17 |
| Regular Market Price | 21.55 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,270,512 |
| Return On Assets | -0.11243 |
| Return On Equity | -0.53472 |
| Revenue Growth | -0.327 |
| Revenue Per Share | 21.956 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 104,989,772 |
| Shares Percent Shares Out | 0.2451 |
| Shares Short | 25,729,261 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 21,243,755 |
| Short Name | Sarepta Therapeutics, Inc. |
| Short Percent Of Float | 0.284 |
| Short Ratio | 7.89 |
| Source Interval | 15 |
| State | MA |
| Symbol | SRPT |
| Target High Price | 38.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 21.78261 |
| Target Median Price | 20.0 |
| Total Cash | 939,649,984 |
| Total Cash Per Share | 8.95 |
| Total Debt | 1,039,548,032 |
| Total Revenue | 2,198,236,928 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.56895 |
| Two Hundred Day Average Change | 1.9810486 |
| Two Hundred Day Average Change Percent | 0.10123428 |
| Type Disp | Equity |
| Volume | 2,270,512 |
| Website | https://www.sarepta.com |
| Zip | 2,142 |